Sanjosé Llongueras, Silvia deSerrano, BeatrizTous, SaraAlejo, MariaLloveras Rubio, BetlemQuirós, BeatrizClavero, OmarVidal-Bel, AugustFerrándiz Pulido, CarlaPavón Ribas, Miquel ÀngelHolzinger, DanaHalec, GordanaTommasino, MassimoQuint, WimPawlita, MichaelMuñoz, NubiaBosch José, Francesc Xavier, 1947-Alemany i Vilches, LaiaRIS HPV TT, VVAP and Head and Neck study groups2020-11-182020-11-182018-11-012515-5091https://hdl.handle.net/2445/172145Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci- nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA- positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi- cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.11 p.application/pdfengcc by-nc (c) Sanjosé Llongueras et al., 2018http://creativecommons.org/licenses/by-nc/3.0/esPapil·lomavirusCàncer de coll uteríPapillomavirusesCervix cancerinfo:eu-repo/semantics/article6839512020-11-18info:eu-repo/semantics/openAccess31360870